Download report sample at: https://www.psmarketresearch.com/market-analysis/ptsd-therapeutics-pipeline-analysis/report-sample
According to the National Center of PTSD, around seven to eight out of 100 individuals experience PTSD at some point in their lives. Most of the people recover from traumatic situation naturally, but those who continue to experience problems are diagnosed with PTSD. People with PTSD are used to feel frightened even when they are not in a dangerous situation. PTSD generally occurs more often in women than men. Various collaboration between educational institutes, associations, and pharma companies are driving the therapeutic pipeline of PTSD.
Many patents have been received during the development of drug candidates for the treatment of PTSD. In May 2017, Tonix reported the issuance of patent 9 636 408 by the United States Patent and Trademark Office titled “Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride,” covering the composition and manufacture of its proprietary sublingual formulation of very low dose cyclobenzaprine.
Browse report at: https://www.psmarketresearch.com/market-analysis/ptsd-therapeutics-pipeline-analysis
Some of the key players developing drugs for the treatment of PTSD include India Globalization Capital, Inc., Therapade Technologies LLC, Axim Biotechnologies, Inc. and others.
About
P&S Intelligence
P&S
Intelligence, a brand of P&S Market Research, is a provider of market
research and consulting services catering to the market information needs of
burgeoning industries across the world. Providing the plinth of market
intelligence, P&S as an enterprising research and consulting company,
believes in providing thorough landscape analyses on the ever-changing market
scenario, to empower companies to make informed decisions and base their
business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886
(USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook
Comments
Post a Comment